Breast Cancer Research and Treatment (2018) 168:283
LETTER TO THE EDITOR
Does tacrolimus have any positive impact on outcome
of post‑transplant breast cancer patients?
Received: 26 October 2017 / Accepted: 22 November 2017 / Published online: 24 November 2017
© Springer Science+Business Media, LLC, part of Springer Nature 2017
I wish to congratulate Jeong and colleagues for their article
 in which the characteristics and prognosis of post-trans-
plant breast cancer (PTBC) patients receiving immunosup-
pressants and general breast cancer patients were compared.
They reported that subtype and prognosis of breast cancer
were comparable with that in the general cohort and immu-
nosuppressants do not adversely aﬀect breast cancer prog-
nosis. In this study, 24 were diagnosed with PTBC. Of the
24 PTBC cohort, 12 received mammalian target of rapa-
mycin (mTOR) inhibitor—tacrolimus as immunosuppres-
sive agent. Results of both the TAMRAD and BOLERO-2
studies showed that mTOR inhibition in combination with
endocrine therapy improved progression-free survival for
hormone receptor-positive metastatic breast cancer patients
. For this reason, it would be interesting to compare the
outcome of hormone receptor-positive PTBC patients who
received endocrine treatment and tacrolimus with hormone
receptor-positive patients in general cohort.
Acknowledgements The author has not received any grants.
Compliance with ethical standards
Conflict of interest I have no conﬂict of interest to declare.
Ethical approval My manuscript complies with the Ethical Rules appli-
cable for this journal.
Research involving human and animal participants This article does
not contain any studies with human participants or animals performed
by the author.
1. Jeong IJ, Lee SG, Kim YH, Ko BS, Lee JW, Son BH, Ahn SH,
Kim HJ (2017) Characteristics and prognosis of breast cancer
after liver or kidney transplantation. Breast Cancer Res Treat.
2. Sendur MA, Zengin N, Aksoy S, Altundag K (2014) Everolimus:
a new hope for patients with breast cancer. Curr Med Res Opin
* Kadri Altundag
MKA Breast Cancer Clinic, Tepe Prime, Cankaya,
06800 Ankara, Turkey